Molbio Diagnostics made a strong debut, beating grey market expectations. Experts remain positive on the company’s molecular diagnostics leadership, expansion strategy and industry prospects, though they advise caution after the sharp initial gains and suggest a Rs 900 stop-loss.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.